P
PREV
vs
S
S&P TSX Composite Index (Canada)
Over the past 12 months, PREV has underperformed S&P TSX Composite Index (Canada), delivering a return of -20% compared to the S&P TSX Composite Index (Canada)'s +36% growth.
Stocks Performance
PREV vs S&P TSX Composite Index (Canada)
Performance Gap
PREV vs S&P TSX Composite Index (Canada)
Performance By Year
PREV vs S&P TSX Composite Index (Canada)
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Preveceutical Medical Inc
Glance View
PreveCeutical Medical, Inc. engages in licensing, branding, and marketing of nutraceutical and wellness products. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2016-12-30. The Company’s principal business activity is the development of options for preventive and curative therapies utilizing organic and nature identical products. Its pipeline include Cannabinoid Sol-Gel, which is a cannabinoid-based nose-to-brain delivery system that provide relief across a range of indications from pain, inflammation, seizures, and neurological disorders; BSV peptide program targeting cancer progression; Non-Addictive Analgesic, which is engineering non-addictive analgesic peptides for pain management. Peptides are used to target a range of disease including metabolic disorders, pain, cancers, cardiovascular and infectious diseases and Dual Gene Therapy, which targets type 2 diabetes and obesity. The Company’s wholly owned subsidiary is PreveCeutical (Australia) Pty Ltd. (PreveCeutical (Australia)). Its research programs are managed by PreveCeutical (Australia).
